ES2070172T3 - Procedimiento para producir proteinas mediante adn recombinante. - Google Patents

Procedimiento para producir proteinas mediante adn recombinante.

Info

Publication number
ES2070172T3
ES2070172T3 ES89303767T ES89303767T ES2070172T3 ES 2070172 T3 ES2070172 T3 ES 2070172T3 ES 89303767 T ES89303767 T ES 89303767T ES 89303767 T ES89303767 T ES 89303767T ES 2070172 T3 ES2070172 T3 ES 2070172T3
Authority
ES
Spain
Prior art keywords
procedure
recombinant dna
producing proteins
host cell
synthesised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89303767T
Other languages
English (en)
Inventor
Raymond John Owens
Gregory Paul Winter
Lutz Riechmann
Geoffrey Thomas Yarranton
Mark William Bodmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2070172(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888809050A external-priority patent/GB8809050D0/en
Priority claimed from GB888811342A external-priority patent/GB8811342D0/en
Priority claimed from GB888820284A external-priority patent/GB8820284D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of ES2070172T3 publication Critical patent/ES2070172T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION PREVEE UN METODO PARA LA PRODUCCION DE FRAGMENTOS FV QUE COMPRENDE: TRANSFORMACION DE UNA CELULA EUCARIOTICA CON UN VECTOR DE EXPRESION AUCARIOTICO QUE COMPRENDE UN OPERON CON UNA SECUENCIA DE DNA QUE CODIFICA PARA UN DOMINIO VARIABLE SOLAMENTE DE UN ANTICUERPO DE CADENA LIGERA O PESADA. CULTIVO DE LA CELULA HUESPED TRANSFORMADA BAJO CONDICIONES QUE CAUSAN LA PROTEINA CODIFICADA POR LA SECUENCIA DE DNA QUE SE VA A SINTETIZAR, Y RECOLECCION DE LA PROTEINA SINTETIZADA. FIG.1.
ES89303767T 1988-04-16 1989-04-17 Procedimiento para producir proteinas mediante adn recombinante. Expired - Lifetime ES2070172T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888809050A GB8809050D0 (en) 1988-04-16 1988-04-16 Expression of antibody heavy & light chain variable domains as an fv-fragment
GB888811342A GB8811342D0 (en) 1988-05-13 1988-05-13 Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
GB888820284A GB8820284D0 (en) 1988-08-26 1988-08-26 Method for producing recombinant dna proteins

Publications (1)

Publication Number Publication Date
ES2070172T3 true ES2070172T3 (es) 1995-06-01

Family

ID=27263864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89303767T Expired - Lifetime ES2070172T3 (es) 1988-04-16 1989-04-17 Procedimiento para producir proteinas mediante adn recombinante.

Country Status (9)

Country Link
EP (1) EP0338745B1 (es)
JP (2) JP3105898B2 (es)
AT (1) ATE119198T1 (es)
AU (1) AU627183B2 (es)
CA (1) CA1341411C (es)
DE (1) DE68921364T2 (es)
ES (1) ES2070172T3 (es)
GR (1) GR3015248T3 (es)
WO (1) WO1989009825A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
EP0861893A3 (en) * 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
JPH11513669A (ja) * 1995-10-13 1999-11-24 アメリカ合衆国 ジスルフィド安定化抗体フラグメントを含む免疫毒素
DE69627685T2 (de) * 1995-10-20 2004-01-29 Novartis Ag Verfahren zur herstellung eines einkettigen fv antikörperfragments
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
JP2000164361A (ja) 1998-11-25 2000-06-16 Tdk Corp 有機ｅｌ素子
JP2003520195A (ja) 1999-05-14 2003-07-02 イムクローン システムズ インコーポレイティド 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
IL152825A (en) 2000-05-16 2009-07-20 Univ Jefferson Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
SI2508596T1 (sl) 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
DK2308507T3 (da) 2002-07-19 2015-04-20 Beth Israel Hospital Fremgangsmåder til behandling af præeklampsi
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
CA2581336C (en) 2004-09-24 2022-10-04 S. Ananth Karumanchi Diagnosis of pregnancy-related hypertensive disorder by measurement of soluble endoglin
CN102397542B (zh) 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
AU2007274738B2 (en) 2006-07-18 2013-11-28 Sanofi-Aventis Antagonist antibody against EphA2 for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2009222998B2 (en) 2008-03-12 2013-05-23 Imclone Llc Anti-TYRP1 antibodies
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
WO2011022472A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
CN102844050B (zh) 2010-02-19 2019-02-05 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (en) * 1982-03-15 1991-06-19 Schering Corporation Hybrid dna, binding composition prepared thereby and processes therefor
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (en) * 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules

Also Published As

Publication number Publication date
JP3105898B2 (ja) 2000-11-06
JPH03500005A (ja) 1991-01-10
JPH11225758A (ja) 1999-08-24
WO1989009825A1 (en) 1989-10-19
AU3536489A (en) 1989-11-03
EP0338745A1 (en) 1989-10-25
DE68921364T2 (de) 1995-06-29
CA1341411C (en) 2002-12-17
DE68921364D1 (de) 1995-04-06
ATE119198T1 (de) 1995-03-15
EP0338745B1 (en) 1995-03-01
GR3015248T3 (en) 1995-06-30
AU627183B2 (en) 1992-08-20

Similar Documents

Publication Publication Date Title
ES2070172T3 (es) Procedimiento para producir proteinas mediante adn recombinante.
DK368588A (da) Bindingsmolekyler med en enkelt polypeptidkaede
GB2137631B (en) Multichain polypeptides and processes for their production
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
PT990044E (pt) Metodo para evolucao molecular in vitro da funcao de proteinas
FI961251A0 (fi) Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
ATE365800T1 (de) Therapeutische verwendungen von il-17 homologe polypeptide
DE3587524T2 (de) Herstellung von chimären antikörpern.
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
EA200000216A1 (ru) Белки, связывающие интерлейкин-18, их получение и применение
PT83761B (pt) Metodo para a producao de interleuquina-4 de mamifero
DK1246917T3 (da) Humane Stra6-polypeptider
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
FI102383B1 (fi) Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
HUP9801330A2 (hu) Új PKA-kötő fehérjék és alkalmazásuk
DK0422217T3 (da) Human, rekombinant, placental ribonucleaseinhibitor og fremgangsmåde til produktion
EP0688224A4 (en) MUTANT PROTEIN, METHODS AND MATERIALS USED FOR ITS MANUFACTURE AND USE
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
DE69721629D1 (de) An Nukleinsäure gebundenes Polypeptid, Verfahren zur Herstellung eines an Nukleinsäure gebundenen Polypeptides und Immunoassay, in dem dieses Polypeptid Verwendung findet
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder
DK1241185T3 (da) Nucleinsyrer, der er opformeret i humane tumorer, samt beslægtede materialer og fremgangsmåder
PT1217006E (pt) Polipeptidos e acidos nucleicos que os codificam

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 338745

Country of ref document: ES